Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 5/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146522 | 0.79 | KDR (0.52) | AOC3KDR | |
| SCHEMBL14435919 | 0.79 | AOC3 (0.47) | AOC3LRRK2ADORA2AHCAR2KDR | |
| SCHEMBL3613448 | 0.78 | AOC3 (0.35) | AOC3LRRK2ADORA2ACYP11B1CYP11B2 | |
| SCHEMBL11516196 | 0.78 | HSD17B1 (0.49) | KDRNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL2405110 | 0.78 | HPGDS (0.43) | AOC3LRRK2ADORA2AHCAR2PIK3CD | |
| SCHEMBL12224191 | 0.78 | LIMK1 (0.51) | AOC3ADORA2AKDRLIMK1NPC1 | |
| SCHEMBL19730877 | 0.76 | APP (0.50) | AOC3LRRK2ADORA2AKDRPIK3CD | |
| SCHEMBL21914541 | 0.76 | HSD17B1 (0.53) | AOC3NPC1RAB9ACYP3A4CYP2C9 | |
| SCHEMBL2405326 | 0.76 | AOC3 (0.44) | AOC3LRRK2ADORA2AKDRNPC1 | |
| SCHEMBL2406713 | 0.76 | AOC3 (0.48) | AOC3LRRK2ADORA2ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624193-B2 | Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component | TOSOH CORPORATION (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20150329544-A1 | CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT | TOSOH CORPORATION (JP) | 2015-11-19 | — | — | US | disclosed |
| US-9120773-B2 | Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component | TOSOH CORPORATION (JP) | 2015-09-01 | — | — | US | disclosed |
| EP-2818462-A1 | Cyclic azine derivatives, processes for producing these, and organic electrolumiscent element containing these as component | TOSOH CORPORATION (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-8497273-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20120214993-A1 | CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT | SAGAMI CHEMICAL RESEARCH INSTITUTE, (JP) | 2012-08-23 | — | — | US | disclosed |
| CN-102574813-A | Cyclic azine derivatives, process for producing the same, and organic electroluminescent element containing the same as constituent | TOSOH CORP | 2012-07-11 | — | — | CN | disclosed |
| EP-2468731-A1 | CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT | Tosoh Corporation (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20100048582-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-02-25 | — | — | US | disclosed |
| CN-101421264-A | Is suitable for treating serotonin 5HT6Heterocyclic compounds for receptor-modulated responsive disorders | ABBOTT GMBH & CO KG (DE) | 2009-04-29 | — | — | CN | disclosed |
| US-20080262052-A1 | METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | PPARD, PPARA, PPARG | AOC3 2204/4885LRRK2 3373/4885ADORA2A 446/4885 |
| US-20150329544-A1 | CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT | CPNE4, EPB41, AZI2 | AOC3 38/4885LRRK2 2102/4885ADORA2A 621/4885 |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | PPARD, PPARG, PPARA | AOC3 1859/4885LRRK2 2789/4885ADORA2A 500/4885 |
| US-20120214993-A1 | CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT | CPNE4, EPB41, AZI2 | AOC3 38/4885LRRK2 2102/4885ADORA2A 621/4885 |
| US-20080262052-A1 | METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | PPARD, PPARG, PPARA | AOC3 1704/4885LRRK2 4470/4885ADORA2A 612/4885 |
| US-20100048582-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | HTR6, HTR1A, HTR2C | AOC3 1547/4885LRRK2 1248/4885ADORA2A 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.